Penicillin Allergy Management in India and Sri Lanka: Current Challenges
Clinical & Experimental Allergy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 23, 2025
ABSTRACT
Data
regarding
Penicillin
allergy
labels
(PALs)
from
India
and
Sri
Lanka
are
sparse.
Emerging
data
suggests
that
the
proportion
of
patients
declaring
an
unverified
PAL
in
secondary
care
(1%–4%)
is
lesser
than
reported
High
Income
Countries
(15%–20%).
However,
even
this
relatively
small
percentage
translates
into
a
large
absolute
number,
as
part
world
accounts
for
approximately
25%
global
population.
There
huge
unmet
need
specialists
Lanka.
management
further
compromised
by
unavailability
skin
test
reagents,
lack
formal
training
drug
allergy,
pre‐emptive,
non‐standardised
unregulated
testing
untrained
operators
weak
health
service
framework.
This
has
adverse
impact
on
antimicrobial
stewardship,
particularly
rheumatic
fever,
heart
disease,
bacterial
endocarditis,
syphilis
other
sexually
transmitted
infections.
narrative
review
highlights
burden
PALs
Lanka,
well
gaps
published
literature.
It
describes
current
challenges
pragmatic,
cautious
staged
bespoke
mitigation
approach
to
improve
standardise
stewardship
accordance
with
World
Health
Organisation
AWaRe
guidance.
Language: Английский
Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life
Vaccine,
Journal Year:
2025,
Volume and Issue:
50, P. 126849 - 126849
Published: Feb. 5, 2025
Concerns
of
potential
drug/vaccine-associated
allergies
significantly
impact
vaccine
safety
and
hesitancy.
Delabelling
incorrect
drug
allergy
in
the
general
public
was
previously
impeded
by
limited
access
to
allergist
services,
especially
among
less
frequent
healthcare
utilisers
community.
COVID-19
evaluation
services
have
enabled
individuals
(mis)labelled
with
receive
vaccinations
safely
provided
opportunities
expand
delabeling
access.
We
investigated
effectiveness
this
coincident
delabelling
its
on
health-related
quality
life
(HRQoL).
recruited
labelled
attending
for
Hong
Kong
between
2021
2022.
Demographics,
comorbidities,
labels,
vaccination
infection
outcomes,
as
well
rates
were
analysed.
HRQoL
measured
before
after
a
subgroup
individuals.
Among
652
individuals,
1456
labels
identified,
anti-infectives
being
most
common
(606,
41.6
%).
Beta-lactam
antibiotics
accounted
55.1
%
(334).
Almost
all
(99.4
%)
proceeded
vaccinations,
an
increased
number
doses
conferring
better
protection.
228
(35.0
underwent
investigations,
successful
223
(97.8
%),
removing
317
(21.8
which
173
(51.8
beta-lactams.
Subgroup
analysis
showed
improved
serial
following
(DrHy-Q
45.0
vs
33.3,
p
<
0.001).
Services
evaluating
not
only
empowered
safely,
but
also
enhanced
public.
Language: Английский
Editorial: Allergy in the Asia Pacific
Frontiers in Allergy,
Journal Year:
2025,
Volume and Issue:
6
Published: Feb. 21, 2025
Approximately
4.7
billion
people,
accounting
for
60%
of
the
global
population,
live
in
Asia
and
Pacific
region,
offers
a
unique
lens
addressing
complexities
allergic
diseases.With
diverse
genetic
backgrounds,
cultural
influences,
environmental
exposures,
healthcare
systems,
region
faces
rising
prevalence
allergies
driven
by
urbanization,
pollution,
lifestyle
changes,
alongside
significant
variation
allergen
sensitization
patterns
prescribing
practices
(1)(2)(3)(4)(5)
.
These
factors
not
only
pose
public
health
challenges
but
also
provide
valuable
opportunities
to
develop
innovative,
tailored
approaches
allergy
diagnosis
management.
This
research
topic
brings
together
impactful
contributions,
highlighting
drug
allergies,
diagnostic
advancements,
collaborative
care
pathways,
all
aimed
at
specific
needs
Asia-Pacific
population.Kan
et
al.
explored
feasibility
an
excipient
registry,
focusing
on
polyethylene
glycol
(PEG)
as
relevant
example
amidst
apprehension
concerning
potential
"allergies"
COVID-19
vaccine
(6)
They
underscored
problem
-the
absence
compulsory
requirement
disclose
ingredients
pharmaceutical
formulations.
Their
study
disclosed
that
information
about
excipients
was
missing
more
than
formulations
Hong
Kong,
posing
substantial
obstacles
precise
patient
safety.
By
advocating
universal
legislative
reforms
mandate
ingredient
disclosure,
authors
addressed
critical
gap
management
laid
groundwork
improved
safety
standards.Chinese
patients
with
chronic
rhinosinusitis
(CRS)
(7)
OD,
prevalent
disabling
characteristic
CRS,
significantly
affects
patients'
quality
life.
findings
demonstrated
strong
correlation
between
these
culturally
adapted
tools,
validating
their
use
this
population.
underscores
importance
tailoring
regional
contexts,
enabling
meaningful
assessments
allergy-related
conditions.Pathway
(SHARP),
multidisciplinary
initiative
severe
spontaneous
urticaria
(CSU)
angioedema
(8)
SHARP
integrates
allergists,
dermatologists,
pharmacists
into
streamlined
referral
system
supported
evidence-based
guidelines.
pathway
emphasizes
biologics,
such
omalizumab,
unresponsive
antihistamines.
fostering
collaboration
optimizing
care,
serves
model
improving
outcomes
resource-limited
settings,
demonstrating
how
pathways
can
address
growing
burden
immunologic
diseases.Another
review
worth
mentioning
is
mini-review
Mak
colleagues
(9)
revealed
beta-lactam
penicillin
Asia-Pacific,
uncovering
key
differences
compared
Western
populations.
investigation
uncovered
lesser
genuine
betalactam
area,
pattern
likely
shaped
prescription
habits.Nevertheless,
misidentification
continues
be
hindrance
efficient
antibiotic
stewardship.
The
advocates
delabeling
initiatives
strategies
reduce
unnecessary
avoidance,
improve
clinical
outcomes,
mitigate
costs.These
articles
shed
light
distinct
across
impact
regionally
tailored,
approaches.
gaps
diagnosis,
management,
policy,
they
offer
insights
extend
beyond
local
contexts.
As
community
works
delivery
advance
knowledge,
Research
Topic
lay
foundation
future
innovation,
collaboration,
practical
solutions
benefit
both
broader
field
immunology
allergy.
Language: Английский
Tackling the burden of β-lactam allergy labels
The Lancet Infectious Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
Food Allergy in Children in China
Clinical & Experimental Allergy,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 6, 2024
ABSTRACT
The
prevalence
of
food
allergies
in
China
seems
to
be
increasing,
but
there
are
limited
studies
describing
the
pattern
across
country.
This
review
highlights
regional
variations
observed
China,
with
data
indicating
a
higher
more
economically
developed
eastern
and
southern
coastal
regions
compared
inland
areas.
Egg
milk
most
common
among
children
under
3
years
old;
for
above
old,
specific
allergens
also
show
differences,
shellfish
being
areas,
while
wheat
fruit
prevalent
northern
regions.
Emerging
peanut
tree
nut
have
been
China's
megacities,
although
remains
relatively
low
Western
countries.
These
geographic
environmental
influences
highlight
complexity
allergy
landscape
need
nuanced
understanding
underlying
drivers.
Despite
growing
burden
allergies,
significant
gaps
exist
effectively
managing
these
conditions
China.
Lack
standardised
diagnostic
tools,
access
oral
challenges
shortage
trained
allergists
pose
major
challenges.
Another
critical
gap
is
availability
affordability
epinephrine
autoinjectors,
essential
life‐threatening
anaphylactic
reactions.
Addressing
systemic
deficiencies
management
infrastructure
will
require
concerted
efforts
from
policymakers,
healthcare
systems
pharmaceutical
companies.
Investing
development
diagnostics,
expanding
speciality
workforce
ensuring
equitable
emergency
care
treatment
options
crucial
steps
towards
improving
health
outcomes
millions
individuals
affected
by
Language: Английский